Plasma Epinephrine Contributes to the Development of Experimental Hypoglycemia-Associated Autonomic Failure
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index; 16 of the 43 sources its claims cite were checked for support.
Abstract
Background: Recurrent hypoglycemia blunts counter-regulatory responses to subsequent hypoglycemic episodes, a syndrome known as hypoglycemia-associated autonomic failure (HAAF). Since adrenergic receptor blockade has been reported to prevent HAAF, we investigated whether the hypoglycemia-associated rise in plasma epinephrine contributes to pathophysiology and reported interindividual differences in susceptibility to HAAF. Methods: To assess the role of hypoglycemia-associated epinephrine responses in the susceptibility to HAAF, 24 adult nondiabetic subjects underwent two 2-hour hyperinsulinemic hypoglycemic clamp studies (nadir 54 mg/dL; 0-2 hours and 4-6 hours) on Day 1, followed by a third identical clamp on Day 2. We challenged an additional 7 subjects with two 2-hour infusions of epinephrine (0.03 μg/kg/min; 0-2 hours and 4-6 hours) vs saline on Day 1 followed by a 200-minute stepped hypoglycemic clamp (90, 80, 70, and 60 mg/dL) on Day 2. Results: Thirteen out of 24 subjects developed HAAF, defined by ≥20% reduction in average epinephrine levels during the final 30 minutes of the third compared with the first hypoglycemic episode (P < 0.001). Average epinephrine levels during the final 30 minutes of the first hypoglycemic episode were 2.3 times higher in subjects who developed HAAF compared with those who did not (P = 0.006). Compared to saline, epinephrine infusion on Day 1 reduced the epinephrine responses by 27% at the 70 and 60 mg/dL glucose steps combined (P = 0.04), with a parallel reduction in hypoglycemic symptoms (P = 0.03) on Day 2. Conclusions: Increases in plasma epinephrine reproduce key features of HAAF in nondiabetic subjects. Marked interindividual variability in epinephrine responses to hypoglycemia may explain an individual’s susceptibility to developing HAAF.
Overview
CoChat Summary
TL;DR
In nondiabetic adults, higher plasma epinephrine responses during initial hypoglycemia predicted susceptibility to experimental hypoglycemia-associated autonomic failure (HAAF), and repeated epinephrine infusions without hypoglycemia reproduced key HAAF features during later hypoglycemia. These findings support plasma epinephrine as a contributor to HAAF pathogenesis.
Key findings
- In Protocol 1, 13 of 24 subjects (54%) developed HAAF, defined as ≥20% reduction in average epinephrine during the final 30 minutes of the third vs first hypoglycemic episode; their epinephrine fell from 906 ± 145 to 550 ± 113 pg/mL (P < 0.001).
- Subjects who developed HAAF had ~2.3 times higher average epinephrine during the final 30 minutes of the first hypoglycemic episode than those who did not (906 ± 145 vs 398 ± 77 pg/mL; P = 0.006); non-HAAF subjects instead increased epinephrine from 398 ± 77 to 542 ± 93 pg/mL (P = 0.04).
- In Protocol 2, antecedent epinephrine infusion vs saline reduced subsequent epinephrine responses by 27% at the 70 and 60 mg/dL glucose steps combined (237 [134, 347] vs 325 [237, 526] pg/mL; P = 0.04), with a parallel reduction in hypoglycemic symptoms (P = 0.03).
- Hypoglycemia symptom scores were significantly lower at glucose steps 70 mg/dL, 60 mg/dL, and 70 and 60 mg/dL combined (P = 0.049, P = 0.048, and P = 0.03, respectively) after epinephrine vs saline infusion.
Methods
- Protocol 1: 24 healthy nondiabetic subjects (age 43 ± 2 years, 21 male, BMI 25.1 ± 0.5 kg/m²) underwent three identical 2-hour hyperinsulinemic hypoglycemic clamps targeting 54 mg/dL: two on Day 1 (0–2 and 4–6 hours) and one on Day 2.
- Protocol 2: 7 healthy male nondiabetic subjects (age 32 ± 4 years, BMI 25.0 ± 0.5 kg/m², HbA1c 5.5 ± 0.1%) were studied in a randomized, crossover, single-blind design with two 2-hour epinephrine infusions (0.03 µg/kg/min) or normal saline on Day 1, followed by a 200-minute stepped hyperinsulinemic hypoglycemic clamp (90, 80, 70, and 60 mg/dL, each 50 minutes) on Day 2.
- Analyses used paired t tests, independent samples t tests, and Wilcoxon matched-pairs signed-rank tests, with P < 0.05 considered significant; statistical analyses were performed using Stata version 15.1.
Limitations
- The authors state that different hypoglycemic clamp techniques were used in the two protocols (single 54 mg/dL target vs stepped 90–60 mg/dL), which could affect the magnitude of findings, though they argue the overall direction should not be affected.
- The authors state that EGP did not differ following epinephrine vs saline, perhaps due to tracer equilibration issues because exogenous glucose was infused throughout; they also note limited data points during the second hypoglycemia episode.
- Evident from the text: Protocol 2 was small (n = 7), male-only, nondiabetic, and single-blind, limiting generalizability; the authors state it remains important to establish whether these observations extend to individuals with type 1 diabetes.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
13 Valid · 0 Not valid · 19 Not checked · 44 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The adrenergic system regulates glucose recovery through activation of both alpha and beta receptors, as supported by delayed glucose recovery during a single episode of hypoglycemia with administration of alpha and/or beta antagonists (29-31).”
What the sources say
- Not checked — no full text of the sourcecites [29] Bolli, 1982, Important role of adrenergic mechanisms in acute glucose counterregulation following insulin-induced hypoglycemia in type I diabetes. Evidence for an effect mediated by beta-adrenoreceptors, Diabetes. source
- Not checked — no full text of the sourcecites [30] Kleinbaum, 1984, Effect of propranolol on delayed glucose recovery after insulin-induced hypoglycemia in normal and diabetic subjects, Diabetes Care. source
- Partly supportedcites [31] Lilavivat, 1981, Adrenergic influence on glucocounterregulation in man, Diabetologia. sourceExperimental — accuracy not yet measured
The Abstract reports that beta blockade with propranolol delayed glucose recovery after severe insulin-induced hypoglycaemia, supporting the beta-receptor part of the claim. It also reports that alpha blockade with phentolamine did not interfere with recovery, so this study does not support delayed recovery with alpha antagonism. The Discussion likewise emphasizes a role for beta-adrenergic mechanisms. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Ramanathan and Cryer have shown that use of alpha and beta antagonists in healthy humans during antecedent hypoglycemic episodes improves the counter-regulatory hormonal response during subsequent hypoglycemia (11).”
What the sources say
- Partly supportedcites [11] Ramanathan, 2011, Adrenergic mediation of hypoglycemia-associated autonomic failure, Diabetes. sourceExperimental — accuracy not yet measured
The Methods describe α- and β-adrenergic antagonists given to healthy adults during day-1 hypoglycemia. The Results and Discussion report that this prevented attenuation of the epinephrine, norepinephrine, and growth-hormone responses during subsequent hypoglycemia. The claim is broader than those findings: glucagon and cortisol responses remained reduced on day 2 despite blockade. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Indeed, we found that only 54% of the studied subjects developed HAAF, based upon 20% or greater reduction in epinephrine response between the first and the third episode of hypoglycemia (4, 16).”
What the sources say
- Partly supportedcites [4] Seaquist, 2017, Hypothalamic glucose transport in humans during experimentally induced hypoglycemia-associated autonomic failure, J Clin Endocrinol Metab. sourceExperimental — accuracy not yet measured
Materials and Methods defines successful HAAF induction as at least a 20% reduction in epinephrine secretion during the third versus first hypoglycemic clamp. But the Results report HAAF in 7 of 11 subjects who completed both protocols and in one additional subject who completed only the hypoglycemic protocol—not 54% of the studied subjects. The copy provides no page numbers for these passages. (LLM, conf=0.90)
- Partly supportedcites [16] Criego, 2005, Brain glucose concentrations in healthy humans subjected to recurrent hypoglycemia, J Neurosci Res. sourceExperimental — accuracy not yet measured
The Results (page unavailable) report a lower epinephrine response in participants with type 1 diabetes and hypoglycemia unawareness than in controls. The paper does not report that 54% developed HAAF, use a 20% reduction as a criterion, or compare responses between first and third hypoglycemic episodes. (LLM, conf=0.78)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“suggesting that multiple pathways in addition to the adrenergic system could be simultaneously involved in the pathogenesis of HAAF (8, 33, 34).”
What the sources say
- Supportedcites [8] Lontchi-Yimagou, 2018, Potential approaches to prevent hypoglycemia-associated autonomic failure, J Investig Med. source
The Conclusions state that HAAF does not develop through a single pathway and list several implicated central pathways, hormones, and nutrients alongside adrenergic receptors. They also propose studying combinations of treatments, consistent with the claim that multiple pathways could be involved simultaneously. (LLM, conf=0.93)
- Partly supportedcites [33] Cryer, 2008, The barrier of hypoglycemia in diabetes, Diabetes. sourceExperimental — accuracy not yet measured
The “Mechanisms of HAAF in diabetes” section discusses several hypotheses and a possible complex cerebral network involved in HAAF, supporting the possibility of more than one mechanism. It does not say that these pathways operate simultaneously or establish that they act independently of the sympathoadrenal system. (LLM, conf=0.82)
- Supportedcites [34] Stanley, 2019, Central mechanisms of glucose sensing and counterregulation in defense of hypoglycemia, Endocr Rev. source
The ‘Impact of Recurrent Hypoglycemia on Counterregulation’ section says changes in neurotransmission and energy metabolism are possible mechanisms of impaired hypoglycemia awareness. It explicitly says the proposed mechanisms are not mutually exclusive and that multiple factors likely contribute, supporting the claim that pathways beyond the adrenergic response could be involved simultaneously. (LLM, conf=0.91)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“as well as a loss of symptom awareness during subsequent hypoglycemic episodes (2).”
What the sources say
- Supportedcites [2] Dagogo-Jack, 2015, Philip E. Cryer, MD: seminal contributions to the understanding of hypoglycemia and glucose Counterregulation and the discovery of HAAF (Cryer Syndrome), Diabetes Care. source
The “Hypoglycemia-Associated Autonomic Failure” section says that HAAF involves hypoglycemia unawareness during subsequent hypoglycemia. The “Case for a New Taxonomy” section describes this as absent or impaired awareness of neurogenic symptoms. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
40 more claims · 1 with their cited sources checked
Create a free account to see all 76 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 13
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Discussion · p. 10
“while we administered two 2-hour-long infusions of epinephrine on day 1 followed by a 2-hour stepped hypoglycemia clamp on day 2”
§ Protocol 2: Experimental induction of HAAF with epinephrine infusions in the absence of hypoglycemia · p. 3
“followed by a single 200-minute stepped hyperinsulinemic hypoglycemic clamp (target glucose levels of 90, 80, 70, and 60 mg/dL, each for 50 minutes) on Day 2”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Protocol 2 · p. 7
“Although there was no statistical significance at glucose step 60 mg/dL, it is worth noting that certain symptoms”
§ Discussion · p. 9
“Number of symptoms reported was significantly lower at glucose steps 70 mg/dL, 60 mg/dL, and steps 70 and 60 mg/dL combined ( P = 0.049, P = 0.048 and P = 0.03, respectively) following epinephrine compared to saline infusions.”
Citations
Cites
INFLUENCES OF GLUCOSE LOADING AND OF INJECTED INSULIN ON HEPATIC GLUCOSE OUTPUT*
Steele, R. (1959) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1959.tb44923.x · Cited by 1,670
The barrier of hypoglycemia in diabetes
Cryer, P. E. (2008) · Diabetes · doi:10.2337/db08-1084 · Cited by 725
Mitrakou, A., Ryan, C., Veneman, T., Mokan, M., Jenssen, T., Kiss, I., Durrant, J., Cryer, P., & Gerich, J. (1991) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1991.260.1.e67 · Cited by 558
Finegood, D. T., Bergman, R. N., & Vranic, M. (1987) · Diabetes · doi:10.2337/diab.36.8.914 · Cited by 546
Heller, S. R., & Cryer, P. E. (1991) · Diabetes · doi:10.2337/diab.40.2.223 · Cited by 531
Mechanisms of hypoglycemia-associated autonomic failure in diabetes
Cryer, P. E. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1215228 · Cited by 433
Diverse causes of hypoglycemia-associated autonomic failure in diabetes.
Cryer, P. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmra031354 · Cited by 411
White, N. H., Skor, D. A., Cryer, P. E., Levandoski, L. A., Bier, D. M., & Santiago, J. V. (1983) · New England Journal of Medicine · doi:10.1056/nejm198303033080903 · Cited by 391
Partitioning the symptoms of hypoglycaemia using multi-sample confirmatory factor analysis
Deary, I. J., Hepburn, D. A., MacLeod, K. M., & Frier, B. M. (1993) · Diabetologia · doi:10.1007/bf00401150 · Cited by 286
Towler, D. A., Havlin, C. E., Craft, S., & Cryer, P. (1993) · Diabetes · doi:10.2337/diab.42.12.1791 · Cited by 258
Cited by
Current and future therapies to treat impaired awareness of hypoglycemia
Macon, E. L., DEVORE, M. H., Lin, Y. K., MUSIC, M. B., WOOTEN, M., McMullen, C. A., Woodcox, A. M., MARKSBURY, A. R., Beckner, Z., Patel, B. V., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1271814 · Cited by 23
Impaired Awareness of Hypoglycemia in Type 1 Diabetes: A Report of An NIDDK Workshop in October 2021
Seaquist, E. R., Teff, K. L., & Heller, S. R. (2022) · Diabetes Care · doi:10.2337/dc22-1242 · Cited by 17
Mitophagy disorder mediates cardiac deterioration induced by severe hypoglycemia in diabetic mice
Huang, C., Huang, L., Huang, Q., Lin, L., Wang, L., Wu, Y., Wu, K., Gao, R., Liu, X., Liu, X., et al. (2023) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2023.111994 · Cited by 9
Park, S., & Kim, E. (2024) · Metabolites · doi:10.3390/metabo14090483 · Cited by 8
Bengtsen, M. B., & Møller, N. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac123 · Cited by 9
“The authors [42] contemplate that interindividual variability in hormonal responses may explain an individual’s susceptibility to HAAF.”
BackgroundMethodInfluential
Metadata
- Authors
- Lontchi-Yimagou, E., Aleksic, S., Hulkower, R., Gospin, R., Goyal, A., Kuo, B., Mitchell, W. G., You, J. Y., Upadhyay, L., Carey, M., Sandu, O. A., Gabriely, I., Shamoon, H., & Hawkins, M.
- Affiliations
- Albert Einstein College of Medicine, Bronx, New York
- Albert Einstein College of Medicine (US)
- NYU Langone Health (US)
- United States Food and Drug Administration (US)
- Corresponding author
- Hawkins, Meredith
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2020-09-09
- Volume
- 105
- Issue
- 11
- Pages
- 3416-3427
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC7678732
- OpenAlex
- W3083871319
- Cited by
- 17
- References
- 58
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 5 · 2023: 2 · 2022: 4 · 2021: 1 · 2020: 1
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK069861, DK079974)
- Einstein-Mount Sinai Diabetes Research Center (5P30DK020541-41)
- National Center for Advancing Translational Sciences
- Einstein-Montefiore Clinical and Translational Science Awards (UL1TR001073, UL1TR002556)
- American Diabetes Association (1-18-PMF-024)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Syncope and Autonomic Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- hypoglycemia-associated autonomic failure, plasma epinephrine, recurrent hypoglycemia, counterregulatory response, adrenergic blockade, epinephrine infusion, interindividual variability, hypoglycemic symptoms, hyperinsulinemic hypoglycemic clamp, non-diabetic patients
- MeSH terms
- Adult, Autonomic Nervous System, Autonomic Nervous System Diseases, Blood Glucose, Epinephrine, Female, Humans, Hypoglycemia, Insulin, Male, Middle Aged, Glucose Clamp Technique
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Plasma Epinephrine Contributes to the Development of Experimental Hypoglycemia-Associated Autonomic Failure. https://app.cochat.ai/papers/10.1210/clinem/dgaa539
- The paper
- Lontchi-Yimagou, E., Aleksic, S., Hulkower, R., Gospin, R., Goyal, A., Kuo, B., Mitchell, W. G., You, J. Y., Upadhyay, L., Carey, M., Sandu, O. A., Gabriely, I., Shamoon, H., & Hawkins, M. (2020). Plasma Epinephrine Contributes to the Development of Experimental Hypoglycemia-Associated Autonomic Failure. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaa539
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.